A new cost-effectiveness modeling study evaluates whether coronary artery calcium scoring can refine cardiovascular risk stratification and help identify obese patients most likely to derive clinical and...
A retrospective cohort study examined whether concurrent menopause hormone therapy modifies weight loss and cardiometabolic outcomes among postmenopausal women with overweight or obesity treated with...
The FDA has cleared a once-daily oral semaglutide treatment for adults with obesity or overweight and weight-related conditions, based on phase 3 OASIS 4 trial results demonstrating significant mean weight...
In a large real-world cohort study comparing semaglutide with metformin, investigators found no significant difference in the risk of incident urinary stone disease. Despite meaningful reductions in BMI...
The Trump administration announced a new agreement with pharmaceutical companies Eli Lilly and Company and Novo Nordisk to reduce the cost of obesity medication and expand access to these treatments.
In adults with type 1 diabetes and obesity using automated insulin delivery, once-weekly semaglutide significantly improved time in range, lowered HbA1c, and reduced body weight by nearly 9 kg compared with...
In a study examining postoperative outcomes 1 year after total knee arthroplasty, researchers explored how changes in pain and function relate to patient satisfaction—and which clinical factors may help...
A retrospective review of patients undergoing elective dental procedures found that dexmedetomidine alone was more often associated with oxygen desaturation, while combining dexmedetomidine with ketamine...
A large cohort study explored whether semaglutide and tirzepatide influence risks of dementia, stroke, and survival in adults with diabetes and obesity.
A large cohort study of adolescents found that higher restricted normalized isotropic (RNI) values—an MRI-based marker of brain microstructure—were associated with greater weight gain over 2 years,...
